Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Remy B. Verheijen; Huixin Yu; Jan H.M. Schellens; Jos H. Beijnen; Neeltje Steeghs; Alwin D.R. Huitema

doi:10.1002/cpt.787

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Remy B. Verheijen, Huixin Yu, Jan H.M. Schellens, Jos H. Beijnen, Neeltje Steeghs, Alwin D.R. Huitema

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

217 Citaten (Scopus)

Samenvatting

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

Originele taal-2	Engels
Pagina's (van-tot)	765-776
Aantal pagina's	12
Tijdschrift	Clinical Pharmacology and Therapeutics
Volume	102
Nummer van het tijdschrift	5
DOI's	https://doi.org/10.1002/cpt.787
Status	Gepubliceerd - nov. 2017
Extern gepubliceerd	Ja

Toegang tot document

10.1002/cpt.787

Citeer dit

@article{6d9e255cf40a4f84825ff56d92e9b9cb,

title = "Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology",

abstract = "Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.",

author = "Verheijen, {Remy B.} and Huixin Yu and Schellens, {Jan H.M.} and Beijnen, {Jos H.} and Neeltje Steeghs and Huitema, {Alwin D.R.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics",

year = "2017",

month = nov,

doi = "10.1002/cpt.787",

language = "English",

volume = "102",

pages = "765--776",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

AU - Verheijen, Remy B.

AU - Yu, Huixin

AU - Schellens, Jan H.M.

AU - Beijnen, Jos H.

AU - Steeghs, Neeltje

AU - Huitema, Alwin D.R.

PY - 2017/11

Y1 - 2017/11

N2 - Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

AB - Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

UR - http://www.scopus.com/inward/record.url?scp=85028910046&partnerID=8YFLogxK

U2 - 10.1002/cpt.787

DO - 10.1002/cpt.787

M3 - Review article

C2 - 28699160

AN - SCOPUS:85028910046

SN - 0009-9236

VL - 102

SP - 765

EP - 776

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 5

ER -

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit